Synthesis and Preclinical Evaluation of an 18F-Labeled Synaptic Vesicle Glycoprotein 2A PET Imaging Probe: [18F]SynVesT-2

  • ACS Chem Neurosci. 2020 Feb 19;11(4):592-603. doi: 10.1021/acschemneuro.9b00618.
Zhengxin Cai  1 ,  Songye Li  1 ,  Wenjie Zhang  1  2 ,  Richard Pracitto  1 ,  Xiaoai Wu  1  2 ,  Evan Baum  1 ,  Sjoerd J Finnema  1 ,  Daniel Holden  1 ,  Takuya Toyonaga  1 ,  Shu-Fei Lin  1 ,  Marcel Lindemann  1 ,  Anupama Shirali  1 ,  David C Labaree  1 ,  Jim Ropchan  1 ,  Nabeel Nabulsi  1 ,  Richard E Carson  1 ,  Yiyun Huang  1
Affiliations
  • 1. PET Center, Department of Radiology and Biomedical Imaging , Yale University , New Haven , Connecticut 06520 , United States.
  • 2. Department of Nuclear Medicine, Laboratory of Clinical Nuclear Medicine , West China Hospital, Sichuan University , Chengdu , Sichuan 610041 , China.
PMID: 31961649 DOI: 10.1021/acschemneuro.9b00618
Abstract

Synaptic vesicle glycoprotein 2A (SV2A) is a 12-pass Transmembrane Glycoprotein ubiquitously expressed in presynaptic vesicles. In vivo imaging of SV2A using PET has potential applications in the diagnosis and prognosis of a variety of neuropsychiatric diseases, e.g., Alzheimer's disease, Parkinson's disease, schizophrenia, multiple sclerosis, autism, epilepsy, stroke, traumatic brain injury, post-traumatic stress disorder, depression, etc. Herein, we report the synthesis and evaluation of a new 18F-labeled SV2A PET imaging probe, [18F]SynVesT-2, which possesses fast in vivo binding kinetics and high specific binding signals in non-human primate brain.

Keywords
Alzheimer’s disease; PET; Parkinson’s disease; SV2A; fluorine-18; non-human primate.
Products